抗甲氧西林金黃色葡萄球菌治療市場：依藥物類別、MOA、藥物來源分類 - 全球預測 2023-2030

預計到 2023 年，全球耐甲氧西林金黃色葡萄球菌治療市場將達到 18.0864 億美元，年複合成長率為 5.74%，預計到 2030 年將成長至驚人的 26.7712 億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球耐甲氧西林金黃色葡萄球菌治療市場至關重要。透過檢驗業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1. 抗甲氧西林金黃色葡萄球菌治療藥物的全球市場規模與預測為何？

2.在預測期內，COVID-19對全球耐甲氧西林金黃色葡萄球菌治療市場的阻礙因素與影響為何？

3.預測期內全球耐甲氧西林金黃色葡萄球菌治療市場需要投資哪些產品/細分市場/應用/領域？

4. 抗甲氧西林金黃色葡萄球菌治療藥物的全球市場競爭策略為何？

5. 抗甲氧西林金黃色葡萄球菌治療藥物全球市場的技術趨勢和法律規範是什麼？

6.全球耐甲氧西林金黃色葡萄球菌治療市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入抗甲氧西林金黃色葡萄球菌治療的全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 感染疾病在世界各地的傳播以及對新治療方法的需求不斷增加
    • 提高對細菌感染疾病的認知
    • 免疫功能低下人群的增加
  • 抑制因素
    • 新興國家缺乏對 MRSA 感染的系統性監測
  • 機會
    • 主要企業增加了研究活動，以開發新的 MRSA 治療方法，並得到政府計劃的支持
    • 增加策略聯盟和投資
  • 任務
    • 低成本學名藥簡介
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 依藥物類別分類的耐甲氧西林金黃色葡萄球菌治療藥物市場

• 頭孢菌素
• 葉酸拮抗
• 胜肽
• 胜肽
• 噁唑烷酮
• 四環素

農業部第7章 耐甲氧西林金黃色葡萄球菌治療藥物市場

• 殺菌劑
• 抑菌的

第8章 按藥源分類的耐甲氧西林金黃色葡萄球菌治療藥物市場

• 半合成
• 合成藥物

第9章 美洲耐甲氧西林金黃色葡萄球菌治療藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太地區耐甲氧西林金黃色葡萄球菌治療市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲耐甲氧西林金黃色葡萄球菌治療藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Methicillin-Resistant Staphylococcus Aureus Drugs Market is forecasted to grow significantly, with a projected USD 1,808.64 million in 2023 at a CAGR of 5.74% and expected to reach a staggering USD 2,677.12 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across Cephalosporin, Folate Antagonist, Lipoglycopeptide, Lipopeptides, Oxazolidinone, and Tetracycline. The Lipopeptides is projected to witness significant market share during forecast period.

Based on MOA, market is studied across Bactericidal Drugs and Bacteriostatic. The Bacteriostatic is projected to witness significant market share during forecast period.

Based on Drug Origin, market is studied across Semisynthetic and Synthetic Drugs. The Synthetic Drugs is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?

6. What is the market share of the leading vendors in the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class, 2022 vs 2030
• 4.3. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by MOA, 2022 vs 2030
• 4.4. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Origin, 2022 vs 2030
• 4.5. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased prevalence of global infections and demand for novel therapies
    • 5.1.1.2. Growing awareness about a bacterial infection
    • 5.1.1.3. Increase in immuno-compromised population
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of systematic surveillance for MRSA infection in developing countries
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in research activities to develop novel MRSA drugs by key players and support by government initiatives
    • 5.1.3.2. Increasing strategic alliances and investments
  • 5.1.4. Challenges
    • 5.1.4.1. Introduction of low-cost generic drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Cephalosporin
• 6.3. Folate Antagonist
• 6.4. Lipoglycopeptide
• 6.5. Lipopeptides
• 6.6. Oxazolidinone
• 6.7. Tetracycline

7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by MOA

• 7.1. Introduction
• 7.2. Bactericidal Drugs
• 7.3. Bacteriostatic

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Origin

• 8.1. Introduction
• 8.2. Semisynthetic
• 8.3. Synthetic Drugs

9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 5. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2022 VS 2030 (%)
• FIGURE 6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2022 VS 2030 (%)
• FIGURE 7. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET DYNAMICS
• FIGURE 9. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 5. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY FOLATE ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOGLYCOPEPTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 12. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY BACTERICIDAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY BACTERIOSTATIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 15. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SEMISYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 27. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 29. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 44. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 46. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 47. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 49. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 99. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 101. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 111. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 113. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 114. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 116. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY MOA, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
• TABLE 144. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 145. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 146. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET LICENSE & PRICING